drugset / Trial / NCT01317927

A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies

NCT01317927

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the plasma concentration and pharmacodynamics effects of warfarin 5 mg, in the presence or absence of belinostat 1,000 mg/m². Pharmacokinetic evaluation of belinostat 1,000 mg/m² and metabolites in the presence of warfarin 5 mg.

Timeline

Start
2010-12
Primary completion
2015-06
Completion
2015-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Belinostat Small molecule 1000 mg/m2 Intravenous
Subject Warfarin Small molecule 5 mg Oral